About Us
At APAC Biotech, we are dedicated to transforming cancer treatment through innovative, personalized therapies. With APCEDEN®, India’s first approved dendritic cell-based immunotherapy, we empower patients with targeted, life-changing solutions.
History Of Immunotherapy
The dendritic cell (DC), first identified in the early 1970s by Ralph Steinman, M.D, were long thought to be too rare to play a significant role in the immune response. Thanks to decades of work by Dr. Steinman, it is now known that dendritic cells are exceptionally powerful initiators of immunity, with the ability to activate an immune response up to 100 times more potent than any other cell in the immune repertoire. Because of this unique talent these dendritic cells are now a major focus of laboratory and clinical study across the globe, and are critical targets in cancer vaccine development.
About APAC Biotech
Founded in 2010, Apac Biotech has been dedicated to enhancing the immune systems of cancer patients through regenerative medicine. Our goal is to offer treatments that are economical, effective, and non-toxic, thereby transforming healthcare solutions and positively impacting global health.
Our flagship product, APCEDEN®, is India’s first dendritic cell-based immunotherapy approved by the Indian Health Regulatory. This innovative therapy works by activating the patient’s immune system to recognize and fight cancer cells, offering a targeted, effective solution that complements or replaces traditional treatments like chemotherapy and radiation. APCEDEN® represents the next generation of cancer care, providing hope for patients with limited treatment options.
APAC Biotech Timeline
2009
Pre-Clinical studies for monocyte-derived dendritic cells and validation of its therapeutic value in cancer patients.
2012
Completion of clinical trials and data analysis concluded.
2013
APAC Biotech files an application for market authorization for APCEDEN® as per the letter from the Drug Controller General of India (DCGI).
2017
APAC Biotech becomes the first Indian Biotechnology company to receive the Post Marketing Study (PMS) approval for its personalized dendritic cell-based immunotherapy, APCEDEN®, by the Indian FDA.
2014
Facility inspection concluded by the CDSCO and ICMR (Indian Council of Medical Research).
2018
Commenced signing agreements from various multi-specialty hospitals PAN India.
2020
APAC Biotech is granted the Indian patent for its dendritic cell-based cancer treatment technology and commences research into GBM (Brain Cancer) and PDAC (Pancreatic Cancer).
2021
In 2021, following the COVID-19 impact, the hospital implemented a comprehensive reorganization to improve resilience, patient care, and operational efficiency.
APAC Biotech Timeline
2009
Pre-Clinical studies for monocyte-derived dendritic cells and validation of its therapeutic value in cancer patients.
2012
Completion of clinical trials and data analysis concluded.
2013
APAC Biotech files an application for market authorization for APCEDEN® as per the letter from the Drug Controller General of India (DCGI).
2014
Facility inspection concluded by the CDSCO and ICMR (Indian Council of Medical Research).
2017
APAC Biotech becomes the first Indian Biotechnology company to receive the Post Marketing Study (PMS) approval for its personalized dendritic cell-based immunotherapy, APCEDEN®, by the Indian FDA.
2018
Commenced signing agreements from various multi-specialty hospitals PAN India.
2020
APAC Biotech is granted the Indian patent for its dendritic cell-based cancer treatment technology and commences research into GBM (Brain Cancer) and PDAC (Pancreatic Cancer).
2021
In 2021, following the COVID-19 impact, the hospital implemented a comprehensive reorganization to improve resilience, patient care, and operational efficiency.
Our Hospital Network
Sir Ganga Ram Hospital
Delhi
Apollo Hospital Indraprastha
Delhi
Medanta Medicity Hospital
Gurugram
Ruby Hall Clinic
Pune
HCG Hospital
Bengaluru
Fortis Hospital
Mohali
Vrinchi Hospital
Hyderabad
Apollo Hospital
Hyderabad
Bhagwan Mahavir Hospital
Jaipur
Scientific Advisory Board
Dr. P.P. Bapsy
Clinical Advisor
Dr. Bapsy is Senior Consultant & Head of the Department of Oncology at Apollo Hospital, Bangalore. Previously she was Head of the Department of Medical Oncology at Kidwai Oncology Hospital, Bangalore. Dr. Bapsy holds the unique distinction of being the first woman in India to obtain D.M. in Medical Oncology
Dr. Ashok Vaid
Clinical Advisor
Dr. Vaid is the Chairman, Cancer Institute- Division of Medical Oncology & Hematology, Medanta-The Medicity, Gurgaon. He has been conferred Padma Shree award by the President of India for contribution to the field of medicine in 2009. He is a renowned oncologist of the country and member of various national and international professional bodies. Dr. Vaid has worked as an independent Consultant for the last 18 years.
Dr. N.K. Mehra
Clinical Advisor
The National Professor (endowed chair of the ICMR) and Ex- Dean (Research) of the All India Institute Of Medical Sciences (AIIMS) in New Delhi
